StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
25
This year
1
Publishing Date
2024 - 01 - 24
1
2023 - 11 - 01
1
2022 - 11 - 15
1
2022 - 11 - 02
1
2022 - 09 - 13
1
2022 - 09 - 06
1
2022 - 07 - 04
1
2022 - 06 - 24
1
2022 - 04 - 13
1
2022 - 03 - 31
1
2022 - 03 - 30
1
2022 - 03 - 15
1
2022 - 03 - 08
1
2022 - 02 - 07
1
2022 - 01 - 04
1
2021 - 12 - 15
1
2021 - 12 - 14
1
2021 - 12 - 08
1
2021 - 11 - 29
2
2021 - 11 - 19
1
2021 - 10 - 18
1
2021 - 09 - 30
1
2021 - 08 - 19
1
2021 - 05 - 06
1
Sector
Communications
1
Health technology
25
Manufacturing
2
Tags
Agreement
12
Alliances
22
Antiviral
12
Application
9
Approval
16
Bioscience
10
Biotech
9
Biotech-bay
48
Biotech-beach
11
Breast cancer
22
Cancer
59
Chmp
11
Clinical-trials-phase-iii
14
Collaboration
23
Conference
14
Covid
14
Covid-19
16
Disease
20
Drug
25
Earnings
17
Events
20
Fda
21
Fda-approvals
10
Financial
23
Financial results
20
Genetown
12
Global
35
Growth
10
Health
13
Hepatitis
19
Hiv
41
Impact
9
Leukemia
10
License
13
Liver
11
Market
48
Money
9
N/a
225
People
19
Pharma
12
Pharmaceutical
10
Phase 2
9
Phase 3
9
Positive
13
Potential
10
Pre-clinical
9
Preclinical
10
Report
20
Research
54
Results
51
Sciences
30
Study
11
T-cell
32
Technology
9
Therapeutics
42
Therapy
52
Treatment
50
Trial
23
Trodelvy
15
Yescarta
14
Entities
3m company
10
Abbott laboratories
65
Abbvie inc.
75
Agilent technologies, inc.
10
Aldeyra therapeutics, inc.
10
Aligos therapeutics, inc.
17
Alnylam pharmaceuticals, inc.
11
Amgen inc.
54
Arcutis biotherapeutics, inc.
11
Ardelyx, inc.
11
Arrival
11
Astellas pharma inc
27
Astrazeneca plc
70
Bausch health companies inc.
22
Baxter international inc.
15
Becton, dickinson and company
34
Bio-rad laboratories, inc.
12
Biogen inc.
28
Boston scientific corporation
13
Bristol-myers squibb company
63
Calliditas therapeutics ab
10
Catalent, inc.
10
Certara inc
11
Charles river laboratories international, inc.
13
Danaher corporation
14
Eli lilly and company
105
Endo international plc
13
Enveric biosciences inc
12
Evotec se
20
Galapagos nv
12
Gilead sciences, inc.
25
Glaxosmithkline plc
110
Hoth therapeutics, inc.
12
I-mab
11
Incyte corporation
33
Intelligent bio solutions inc
19
Ionis pharmaceuticals, inc.
14
Jaguar health, inc.
33
Johnson & johnson
225
Laboratory corporation of america holdings
14
Lantern pharma inc.
34
Lexaria bioscience corp
11
Mannkind corporation
12
Medtronic plc
24
Nanoviricides, inc.
21
Novartis ag
116
Novo nordisk a/s
18
Orange
27
Perrigo company
13
Pfizer, inc.
54
Sanofi
244
Sorrento therapeutics, inc.
11
Sutro biopharma, inc.
12
Takeda pharmaceutical company limited
30
Teva pharmaceutical industries ltd
44
Thermo fisher scientific inc
48
Tonix pharmaceuticals holding corp.
12
Viatris inc.
15
West pharmaceutical services, inc.
14
Zai lab limited
11
Symbols
ABBV
4
ABT
1
ADCT
1
ALPMF
1
ALPMY
1
AMGN
2
AUTL
1
AZN
1
AZNCF
1
BMY
4
CPIX
1
EXEL
1
FNCTF
1
GILD
25
GLAXF
4
GMAB
1
GNMSF
1
GSK
4
GTHX
2
IMGN
1
JNJ
5
LLY
1
MNKD
1
NVS
4
NVSEF
3
PFE
2
SNY
4
SNYNF
3
SRNE
1
STRO
1
TAK
2
TEVJF
1
THTX
1
UCBJF
1
UCBJY
1
UTHR
1
ZYME
1
Exchanges
Nasdaq
25
Nyse
8
Crawled Date
2024 - 01 - 24
1
2023 - 11 - 01
1
2022 - 11 - 15
1
2022 - 11 - 02
1
2022 - 09 - 13
1
2022 - 09 - 06
1
2022 - 07 - 04
1
2022 - 06 - 24
1
2022 - 04 - 13
1
2022 - 03 - 31
2
2022 - 03 - 15
1
2022 - 03 - 08
1
2022 - 02 - 07
1
2022 - 01 - 04
1
2021 - 12 - 15
2
2021 - 12 - 08
1
2021 - 11 - 29
2
2021 - 11 - 19
1
2021 - 10 - 18
1
2021 - 09 - 30
1
2021 - 08 - 19
1
2021 - 05 - 06
1
Crawled Time
01:00
7
11:00
3
12:00
2
13:00
3
14:00
1
15:00
1
16:00
1
17:00
1
18:00
1
19:00
2
21:00
1
22:00
1
23:00
1
Source
www.biospace.com
9
www.globenewswire.com
1
www.prnewswire.com
15
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Drug
entities :
Gilead sciences, inc.
save search
Global CAR T-Cell Therapy Market Analysis Report 2023: Drug type, Indication, Target Antigen, End-user and Region - Forecast to 2030
Published:
2024-01-24
(Crawled : 17:00)
- prnewswire.com
PFE
|
News
4
|
$26.27
-0.19%
0.19%
18M
|
Health Technology
|
-7.6%
|
O:
0.39%
H:
0.82%
C:
-0.74%
NVS
|
News
|
$98.35
1.1%
0.69%
2.1M
|
Health Technology
|
-8.71%
|
O:
0.22%
H:
0.43%
C:
-0.39%
SRNE
|
$0.02
33.33%
-8.85%
97K
|
Health Technology
|
-66.67%
|
O:
-63.33%
H:
263.64%
C:
127.27%
GILD
|
$67.08
0.08%
0.06%
6.2M
|
Health Technology
|
-15.6%
|
O:
0.1%
H:
0.43%
C:
-0.04%
AUTL
|
$4.21
-6.03%
-5.91%
2.7M
|
Health Technology
|
-23.73%
|
O:
-0.91%
H:
11.52%
C:
4.94%
drug
report
t-cell
global
therapy
market
Kadcyla Leads the Global Antibody Drug Conjugates Market with Extensive Use in Breast Cancer Treatment
Published:
2023-11-01
(Crawled : 18:00)
- prnewswire.com
ALPMY
|
News
|
$9.47
-0.21%
-1.11%
400K
|
Manufacturing
|
-22.11%
|
O:
-1.46%
H:
3.67%
C:
3.26%
ZYME
|
$8.55
-0.12%
-0.06%
240K
|
Health Technology
|
21.79%
|
O:
1.14%
H:
0.42%
C:
-0.7%
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
-3.08%
|
O:
1.03%
H:
0.73%
C:
0.58%
ADCT
|
$4.78
-3.82%
1.88%
280K
|
Health Technology
|
612.26%
|
O:
-0.16%
H:
6.42%
C:
4.49%
ABBV
|
News
|
$167.8
-1.03%
-0.02%
2.9M
|
Health Technology
|
17.78%
|
O:
-0.86%
H:
0.0%
C:
0.0%
STRO
|
$3.47
-6.72%
-7.2%
730K
|
Health Technology
|
34.5%
|
O:
0.39%
H:
3.86%
C:
3.86%
IMGN
|
News
|
$31.23
0.03%
49M
|
Health Technology
|
109.1%
|
O:
5.09%
H:
5.48%
C:
-1.27%
GILD
|
$67.08
0.08%
0.06%
6.2M
|
Health Technology
|
-16.35%
|
O:
-0.47%
H:
1.88%
C:
1.78%
EXEL
|
$23.71
1.8%
1.73%
1.6M
|
Health Technology
|
12.8%
|
O:
-2.62%
H:
1.17%
C:
-1.66%
drug
antibody
breast
cancer
treatment
global
market
Lyndra Therapeutics’ LYNX™ Drug Delivery Platform Wins 2022 Fierce Life Sciences Innovation Award for Drug Delivery Technology
Published:
2022-11-15
(Crawled : 21:00)
- biospace.com/
GILD
|
$67.08
0.08%
0.06%
6.2M
|
Health Technology
|
-19.03%
|
O:
0.34%
H:
0.61%
C:
-0.16%
award
sciences
drug
life
technology
innovation
platform
U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients
Published:
2022-11-02
(Crawled : 12:00)
- biospace.com/
GILD
|
$67.08
0.08%
0.06%
6.2M
|
Health Technology
|
-15.45%
|
O:
-1.46%
H:
2.33%
C:
-0.38%
vemlidy
treatment
hepatitis
drug
virus
food
infection
chronic hepatitis b
Global Pulmonary Arterial Hypertension Drug Market to Surpass US$ 11,220.2 Million by 2030 - Coherent Market Insights
Published:
2022-09-13
(Crawled : 19:00)
- prnewswire.com
GLAXF
|
News
|
$19.54
-3.77%
-14.18%
170
|
Health Technology
|
29.11%
|
O:
-4.98%
H:
7.63%
C:
2.67%
NVS
|
News
|
$98.35
1.1%
0.69%
2.1M
|
Health Technology
|
20.01%
|
O:
-0.55%
H:
0.42%
C:
-0.72%
GSK
|
News
|
$40.86
-0.92%
1.25%
1.6M
|
Health Technology
|
29.18%
|
O:
-0.6%
H:
0.41%
C:
-0.76%
UTHR
|
$237.0
1.08%
1.09%
670K
|
Health Technology
|
9.43%
|
O:
0.63%
H:
0.81%
C:
0.57%
MNKD
|
$4.19
0.72%
0.72%
2.2M
|
Health Technology
|
9.97%
|
O:
0.0%
H:
5.91%
C:
3.67%
GILD
|
$67.08
0.08%
0.06%
6.2M
|
Health Technology
|
3.04%
|
O:
-1.06%
H:
1.63%
C:
1.2%
drug
global
hypertension
market
Disease-Modifying Antirheumatic Drug (DMARD) Market to Surpass US$ 27,167.8 Million by 2030 - Coherent Market Insights
Published:
2022-09-06
(Crawled : 19:00)
- prnewswire.com
SNYNF
|
News
|
$94.0
-0.27%
-2.18%
310
|
Health Technology
|
18.76%
|
O:
-3.02%
H:
0.0%
C:
0.0%
UCBJY
|
$64.79
-0.72%
-4.38%
3.4K
|
Manufacturing
|
88.62%
|
O:
0.73%
H:
2.28%
C:
1.72%
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
-9.66%
|
O:
-0.65%
H:
0.93%
C:
0.71%
BMY
|
$48.86
-0.27%
0.98%
14M
|
Health Technology
|
-28.83%
|
O:
0.03%
H:
1.18%
C:
0.13%
ABBV
|
News
|
$167.8
-1.03%
-0.02%
2.9M
|
Health Technology
|
21.96%
|
O:
-0.03%
H:
1.08%
C:
0.84%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
19.1%
|
O:
0.49%
H:
0.0%
C:
0.0%
GILD
|
$67.08
0.08%
0.06%
6.2M
|
Health Technology
|
5.82%
|
O:
0.44%
H:
2.03%
C:
1.76%
CPIX
|
$1.61
-1.83%
-1.86%
4.5K
|
Health Technology
|
-27.15%
|
O:
-4.52%
H:
7.12%
C:
5.69%
AMGN
|
News
|
$273.01
-0.19%
-0.17%
1.5M
|
Health Technology
|
12.71%
|
O:
0.24%
H:
1.04%
C:
0.82%
drug
market
A $41.8 Billion Global Opportunity for Small Molecule Drug Discovery by 2026 - New Research from StrategyR
Published:
2022-07-04
(Crawled : 11:00)
- prnewswire.com
PFE
|
News
4
|
$26.27
-0.19%
0.19%
18M
|
Health Technology
|
Email alert
Add to watchlist
GSK
|
News
|
$40.86
-0.92%
1.25%
1.6M
|
Health Technology
|
Email alert
Add to watchlist
AZN
|
News
|
$71.2
0.49%
0.46%
5.4M
|
Health Technology
|
Email alert
Add to watchlist
GLAXF
|
News
|
$19.54
-3.77%
-14.18%
170
|
Health Technology
|
Email alert
Add to watchlist
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
Email alert
Add to watchlist
AZNCF
|
News
|
$135.35
-3.53%
-4.19%
400
|
Health Technology
|
Email alert
Add to watchlist
GILD
|
$67.08
0.08%
0.06%
6.2M
|
Health Technology
|
Email alert
Add to watchlist
TEVJF
|
News
|
$12.37
-24.22%
380
|
Health Technology
|
Email alert
Add to watchlist
BMY
|
$48.86
-0.27%
0.98%
14M
|
Health Technology
|
Email alert
Add to watchlist
drug
research
Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
Published:
2022-06-24
(Crawled : 13:00)
- biospace.com/
GILD
|
$67.08
0.08%
0.06%
6.2M
|
Health Technology
|
8.51%
|
O:
1.52%
H:
0.0%
C:
0.0%
chmp
hiv
positive
drug
Antiviral Drugs Market Size To Reach USD 50.02 BN In 2030 Due to Development Of New, Improved, And More Advanced Formulations, Such As Repurposed Drugs And Drug Combination Therapies, Says Reports and Data
Published:
2022-04-13
(Crawled : 15:00)
- prnewswire.com
GLAXF
|
News
|
$19.54
-3.77%
-14.18%
170
|
Health Technology
|
-30.2%
|
O:
1.76%
H:
0.35%
C:
0.35%
NVSEF
|
News
|
$96.0
0.94%
6.88%
0
|
Health Technology
|
25.63%
|
O:
0.45%
H:
0.0%
C:
-0.83%
NVS
|
News
|
$98.35
1.1%
0.69%
2.1M
|
Health Technology
|
6.13%
|
O:
0.12%
H:
0.44%
C:
0.17%
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
-17.5%
|
O:
0.08%
H:
0.0%
C:
0.0%
GSK
|
News
|
$40.86
-0.92%
1.25%
1.6M
|
Health Technology
|
-12.65%
|
O:
-0.24%
H:
0.45%
C:
0.39%
BMY
|
$48.86
-0.27%
0.98%
14M
|
Health Technology
|
-36.17%
|
O:
0.24%
H:
0.53%
C:
0.18%
ABBV
|
News
|
$167.8
-1.03%
-0.02%
2.9M
|
Health Technology
|
0.29%
|
O:
-1.38%
H:
0.0%
C:
-3.67%
GILD
|
$67.08
0.08%
0.06%
6.2M
|
Health Technology
|
8.84%
|
O:
-0.02%
H:
0.8%
C:
0.71%
drug
antiviral
repurposed
market
Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
Published:
2022-03-30
(Crawled : 01:00)
- biospace.com/
GILD
|
$67.08
0.08%
0.06%
6.2M
|
Health Technology
|
10.82%
|
O:
-0.18%
H:
0.53%
C:
-1.26%
drug
application
cancer
breast cancer
Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
Published:
2022-03-31
(Crawled : 01:00)
- prnewswire.com
GILD
|
$67.08
0.08%
0.06%
6.2M
|
Health Technology
|
12.44%
|
O:
0.52%
H:
0.08%
C:
-0.87%
drug
application
cancer
breast cancer
Coronavirus (COVID-19) Current Therapy Market Sees Antiviral Drugs Accounting For A Large Number Of Treatments
Published:
2022-03-15
(Crawled : 16:00)
- prnewswire.com
GILD
|
$67.08
0.08%
0.06%
6.2M
|
Health Technology
|
15.36%
|
O:
0.47%
H:
0.62%
C:
-0.18%
covid-19
viral drug
treatment
drug
covid
therapy
antiviral
Hematological Malignancies Drugs Market worth $ 42.78 Billion by 2030 - Exclusive Report by InsightAce Analytic
Published:
2022-03-08
(Crawled : 11:00)
- prnewswire.com
GNMSF
|
News
|
$290.34
0.23%
3.83%
1.2K
|
Health Technology
|
-9.97%
|
O:
-0.14%
H:
5.36%
C:
5.36%
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
-11.15%
|
O:
-2.75%
H:
0.28%
C:
-1.04%
JNJ
|
News
|
$148.53
-0.69%
0.18%
7.5M
|
Health Technology
|
-12.0%
|
O:
1.89%
H:
0.0%
C:
0.0%
GSK
|
News
|
$40.86
-0.92%
1.25%
1.6M
|
Health Technology
|
2.87%
|
O:
0.38%
H:
1.81%
C:
0.28%
BMY
|
$48.86
-0.27%
0.98%
14M
|
Health Technology
|
-29.19%
|
O:
-1.55%
H:
0.71%
C:
-0.28%
ABBV
|
News
|
$167.8
-1.03%
-0.02%
2.9M
|
Health Technology
|
12.95%
|
O:
0.29%
H:
0.6%
C:
-1.24%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
-2.84%
|
O:
3.03%
H:
0.0%
C:
0.0%
GILD
|
$67.08
0.08%
0.06%
6.2M
|
Health Technology
|
12.93%
|
O:
1.4%
H:
0.7%
C:
-1.15%
GMAB
|
News
|
$28.47
-0.32%
-0.32%
430K
|
Health Technology
|
-10.49%
|
O:
-0.3%
H:
3.38%
C:
0.32%
AMGN
|
News
|
$273.01
-0.19%
-0.17%
1.5M
|
Health Technology
|
17.92%
|
O:
0.35%
H:
0.0%
C:
0.0%
ema
drug
report
Everest Medicines Announces First Drug Approval of Trodelvy® in Singapore for Second-Line Metastatic Triple-Negative Breast Cancer
Published:
2022-02-07
(Crawled : 01:00)
- prnewswire.com
GILD
|
$67.08
0.08%
0.06%
6.2M
|
Health Technology
|
3.32%
|
O:
-1.42%
H:
0.0%
C:
0.0%
trodelvy
drug
approval
cancer
negative
breast cancer
Everest Medicines Announces Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
Published:
2022-01-04
(Crawled : 01:00)
- prnewswire.com
GILD
|
$67.08
0.08%
0.06%
6.2M
|
Health Technology
|
-7.16%
|
O:
0.4%
H:
0.0%
C:
0.0%
new drug
fda
application
drug
cancer
negative
breast cancer
Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea
Published:
2021-12-14
(Crawled : 01:00)
- biospace.com/
GILD
|
$67.08
0.08%
0.06%
6.2M
|
Health Technology
|
-4.34%
|
O:
-0.37%
H:
0.0%
C:
0.0%
new drug
application
drug
cancer
negative
breast cancer
Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea
Published:
2021-12-15
(Crawled : 01:00)
- prnewswire.com
GILD
|
$67.08
0.08%
0.06%
6.2M
|
Health Technology
|
-3.98%
|
O:
0.99%
H:
1.23%
C:
0.94%
new drug
application
drug
cancer
negative
breast cancer
Global HIV-1 Market and Epidemiology Overview 2018-2030 with Insights Into Marketed & Emerging Drugs from Merck Sharp & Dohme, Gilead Sciences, and ViiV Healthcare
Published:
2021-12-08
(Crawled : 11:00)
- prnewswire.com
SNYNF
|
News
|
$94.0
-0.27%
-2.18%
310
|
Health Technology
|
-1.52%
|
O:
-2.14%
H:
0.34%
C:
0.34%
THTX
|
$1.29
-12.78%
8.1K
|
Health Technology
|
-58.39%
|
O:
-2.48%
H:
4.46%
C:
3.5%
SNY
|
News
|
$46.61
-2.27%
-2.21%
1.6M
|
Health Technology
|
0.01%
|
O:
1.54%
H:
0.0%
C:
0.0%
GILD
|
$67.08
0.08%
0.06%
6.2M
|
Health Technology
|
-3.36%
|
O:
0.72%
H:
0.82%
C:
-0.29%
thc
drug
hiv
G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC)
Published:
2021-11-29
(Crawled : 13:00)
- biospace.com/
GILD
|
$67.08
0.08%
0.06%
6.2M
|
Health Technology
|
-4.19%
|
O:
0.74%
H:
0.0%
C:
0.0%
GTHX
|
$3.99
-4.77%
-5.28%
340K
|
Health Technology
|
-69.95%
|
O:
0.75%
H:
0.82%
C:
-6.28%
phase 2
trilaciclib
antibody
drug
trial
therapeutics
G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC), Trodelvy® (Sacituzumab Govitecan-Hziy)
Published:
2021-11-29
(Crawled : 12:00)
- globenewswire.com
GILD
|
$67.08
0.08%
0.06%
6.2M
|
Health Technology
|
-4.19%
|
O:
0.74%
H:
0.0%
C:
0.0%
GTHX
|
$3.99
-4.77%
-5.28%
340K
|
Health Technology
|
-69.95%
|
O:
0.75%
H:
0.82%
C:
-6.28%
trodelvy
phase 2
trilaciclib
antibody
drug
trial
therapeutics
← Previous
1
2
Next →
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4253
179.25%
64.77%
210M
|
Consumer Services
BOF
|
$2.08
77.78%
41.21%
110M
|
ILAG
|
$0.54
12.27%
40.62%
3.7M
|
LICN
|
$0.999
78.39%
40.49%
15M
|
AMST
|
$3.4
70.0%
39.58%
70M
|
Technology Services
MTC
|
$3.6
60.71%
38.04%
9.1M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.458
14.5%
30.92%
91K
|
Health Services
WHLM
|
$6.25
35.87%
28.46%
700K
|
Commercial Services
MULN
|
News
|
$3.77
38.1%
27.78%
13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.